Gynecology Drugs Market Report 2026

Gynecology Drugs Market Overview

• Gynecology Drugs market size has reached to $45.06 billion in 2025 • Expected to grow to $58.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Surge In Ovarian Cancer Cases Propels Growth In The Global Gynecological Drugs Market • Market Trend: Launch of New Hormone Replacement Therapy (HRT) Prescription Prepayment Certificate (PPC) in the UK • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gynecology Drugs Market?

Gynecology drugs refer to a field of medicine that focuses on the treatment of illnesses of the female reproductive system, including care for women during pregnancy and childbirth. These drugs are used to treat gynecological diseases which include conditions affecting the uterus, ovaries, and appendages. The main types of therapeutics in gynecology drugs are hormonal therapy and non-hormonal therapy. Hormonal therapy is a treatment that adds, blocks, or removes hormones to slow or stop the growth of cancer cells that need hormones to grow. Non-hormonal therapy involves the usage of anti-infective, anti-inflammatory agents, lubricants, moistures, antidepressants, gabapentin, clonidine, and others. Gynecology drugs are used for gynecology cancers, menopausal disorders, polycystic ovary syndrome, contraception, and others and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Gynecology Drugs Market Growth Forecast?

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $58.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to advancement in personalized medicine, growth in telemedicine adoption, increased investment in reproductive health research, development of minimally invasive drug delivery systems, expansion of online pharmacy channels. Major trends in the forecast period include personalized gynecology treatments, telemedicine & remote consultations, minimally invasive drug delivery, growth in fertility and reproductive health therapies, rising awareness of women’s health issues.

Global Gynecology Drugs Market Segmentation

1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Hormonal Therapy: Estrogen Replacement Therapy, Progesterone Therapy, Combination Hormonal Therapy 2) By Non-Hormonal Therapy: Antidepressants (For menopausal symptoms), Non-Hormonal Anticonvulsants, Herbal And Dietary Supplements

What Is The Driver Of The Gynecology Drugs Market?

The rise in the number of women suffering from ovarian cancer would drive the growth of the global gynecological drugs market. Ovarian cancer is a type of cancer that originates in the ovaries, which are part of the female reproductive system. Gynecological drugs contribute significantly to the management of ovarian cancer by providing targeted and effective treatment options, improving survival rates, and enhancing the quality of life for patients. For instance, in February 2023, according to the National Center for Biotechnology Information, a US-based government agency, the global incidence of ovarian cancer is projected to increase to 434,184 new cases, with an estimated 293,039 deaths by 2040. The increasing incidence of ovarian cancer would boost the market for gynecological drugs in the forecast period.

Key Players In The Global Gynecology Drugs Market

Major companies operating in the gynecology drugs market are Pfizer Inc., Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals, Organon & Co., Allergan plc, Gedeon Richter, Besins Healthcare, Theramex, Amgen Inc., Agile Therapeutics, Sanofi S.A., Novartis AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca Plc, Cipla Limited, Kissei Pharmaceutical, Shionogi, Mylan N.V., Bristol‑Myers Squibb Company, Endo International PLC, Apothecus Pharmaceutical Corp., Ani Pharmaceuticals, Medicines360, Blairex Laboratories

Global Gynecology Drugs Market Trends and Insights

Major companies operating in the gynecology drug market are prioritizing the development of innovative therapies such as hormone replacement therapy to gain competitive edge. Hormone Replacement Therapy (HRT) refers to a medical treatment that involves the administration of hormones to alleviate symptoms associated with menopause, such as hot flashes, night sweats, mood swings, and vaginal dryness, thereby improving the overall quality of life for women experiencing these changes. For instance, in April 2023, Department of Health and Social Care, a UK-based government administration, in collaboration with NHS England and the NHS Business Services Authority, a UK-based non-departmental public body, launched new Hormone Replacement Therapy (HRT) prescription prepayment certificate (PPC). The new Hormone Replacement Therapy (HRT) prescription prepayment certificate (PPC) allows women in England to access HRT for just £19.30 per year (approximately $24.50 USD), significantly reducing the financial burden of managing menopause symptoms.

What Are Latest Mergers And Acquisitions In The Gynecology Drugs Market?

In June 2025, Medicus Pharma Ltd., a US-based pharmaceutical company, acquired Antev Limited Ltd. for an undisclosed amount. With this acquisition, Medicus Pharma Ltd. aims to expand its product portfolio, strengthen its market presence in specialty pharmaceuticals, enhance operational capabilities, and drive growth across its therapeutic segments. Antev Limited Ltd. is a UK-based clinical-stage biotechnology company that offers gynecology drugs.

Regional Insights

North America was the largest region in the gynecology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gynecology Drugs Market?

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gynecology Drugs Market Report 2026?

The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.